AstraZeneca says the COVID-19 drug neutralizes omicron variants
AstraZeneca says the COVID-19 drug neutralizes omicron variants

AstraZeneca says the COVID-19 drug neutralizes omicron variants

AstraZeneca said on Monday that its antiviral drug has been shown to be effective in neutralizing the COVID-19 omicron variant, including the newer BA.2 variant, which is increasing the number of cases in Europe and Asia.

Data from the Washington University School of Medicine showed that AstraZeneca’s Evusheld was effective in reducing the viral load and inflammation in the lungs caused by the BA.1, BA.1.1 and BA.2 variants, the company said. The study was performed with mice infected with the virus.

Evusheld has already received an emergency use permit from the Food and Drug Administration (FDA) as a pre-exposure prophylaxis for adults and children as young as 12 years old, weighing at least 88 pounds.

“The results show that Evusheld was effective in protecting against infection in the lungs, a critical disease site for severe COVID-19, across all tested Omicron subvariants,” said Michael Diamond, professor of molecular microbiology, pathology and immunology at Washington University. . as a researcher in the mouse study.

“The findings further support Evusheld as a potentially important opportunity to help protect vulnerable patients, such as immunocompromised ones, who could face poor outcomes should they become infected with COVID-19,” said John Perez, AstraZeneca’s vice president.


Leave a Reply

Your email address will not be published.